Nov13
Session 6:
Clinical stroke trials
Chairs: Hanne Christensen (DK) and Martin Köhrmann (DE)
Secretary: Konstantinos Kostulas (SE)
08:30 – 08:45
How do we increase the generalisability of future stroke trials especially as to women and the old?
Speaker: Hanne Christensen (DK)
08:45 – 09:00
Clinical end-point trials for prolonged cardiac monitoring in stroke: needed
Speaker: Martin Köhrmann (DE)
09:00 – 09:15
Clinical end-point trials for prolonged cardiac monitoring in stroke: needless
Speaker: Georgios Tsivgoulis (GR)
09:15 – 09:30
Presentation of Draft Consensus Statement & Discussion
Speaker: Secretary and Chairs
Short session 7:
Post-stroke dysphagia
Chair: Niaz Ahmed (SE)
09:30 – 09:45
Swallowing test and beyond
Speaker: Emilia Michou (UK)
09:45 – 09:50
Discussion
Coffee Break
Short session 8:
Post-stroke early mobilization
Chair: Niaz Ahmed (SE)
10:25 – 10:40
Should we avoid early mobilisation after AVERT?
Speaker: Katharina Sunnerhagen (SE)
10:40 – 10:45
Discussion
Session 9:
Oral anticoagulation and reversal agents after stroke
Chairs: Joji Kuramatsu (DE) and Thorsten Steiner (DE)
Secretary: Boris Keselman (SE)
10:45 – 11:00
Use of reversal agents for anticoagulation in the setting of acute stroke (ischemic stroke eligible to revascularization or intracerebral hemorrhage)
Speaker: Jan Purrucker (DE)
11:00 – 11:15
Reinitiation of antithrombotics after ICH
Speaker: Eleni Korompoki (UK)
11:15 – 11:30
Antithrombotic management in patients with atrial fibrillation and microbleeds
Speaker: Andreas Charidimou (UK/USA)
11:45 – 12:00
Presentation of Draft Consensus Statement & Discussion
Speaker: Secretary and Chairs
Lunch and Poster exhibition
Industry Symposium Boehringer Ingelheim:
Secondary stroke prevention in 2018 and beyond
Chair: Martin Grond
Setting the stage: a closer look at NO ACs for stroke
prevention
Speaker: Martin Grond, DE
Stroke prevention in AF: latest evidence with NO ACs
Speaker: Robin Lemmens, BE
Practical management of dabigatran and idarucizumab
in acute stroke
Speaker: Thorsten Steiner, DE
Cryptogenic stroke: where does embolic stroke of
undetermined source (ESUS) fit in?
Speaker: Martin Grond, DE
Panel discussion and Q&A Moderated by Martin Grond
Session 10:
IVT in acute ischaemic stroke
Chairs: Götz Thomalla (DE) and Robert Mikulik (CZ)
Secretary: Michael Mazya (SE)
13:00 – 13:15
Thrombolysis in minor stroke- No need for IVT in minor stroke
Speaker: Pooja Khatri (USA)
13:15 – 13:30
Thrombolysis in minor stroke: There is still good evidence to continue treating minor stroke with IVT
Speaker: William Whiteley (UK)
13:30 – 13:45
Criteria for identification of possible candidates for late IVT (Wake up or unknown time of onset)
Speaker: Götz Thomalla (DE)
13:45 – 14:00
Should tenecteplase replace alteplase in routine care?
Speaker: Eivind Berge (NO)
14:00 – 14:15
Presentation of Draft Consensus Statement & Discussion
Speaker: Secretary and Chairs
14:15 – 14:30
Discussion
Coffee Break
Session 11:
Mechanical thrombectomy
Chairs: Gary A. Ford (UK) and Joan Marti-Fabregas (ES)
Secretary: Åsa Kuntze Söderqvist (SE)
15:00 – 15:15
Intravenous thrombolysis before endovascular treatment: beneficial or just dangerous?
Speaker: Diederik W. J. Dippel (NL)
15:15 – 15:30
Thrombectomy beyond the conventional therapeutic window and in unwitnessed stroke
Speaker: Satu Mustanoja (FI)
15:30 – 15:45
Conscious sedation or general anaesthesia in patients undergoing endovascular procedures
Speaker: Mads Rasmussen (DK)
15:45 – 16:00
Critical review of the ESO-ESMINT guideline
Speaker: Gary A. Ford (UK)
16:00 – 16:15
Presentation of Draft Consensus Statement
Speaker: Secretary and Chairs
16:15 – 16:30
Discussion